Calamos Advisors’s Repligen RGEN Stock Holding History

Calamos Advisors’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-127,000	Closed	-$36.7M	–	1153
2021 Q3	$36.7M	Buy	+127,000	New	+$32.6M	0.16%	164

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Calamos Advisors's RGEN Position: Q1 2026 in Review

Calamos Advisors sold out of Repligen (RGEN) in Q1 2026, closing a stake of 3,362 shares — an estimated $551K sold.

Calamos Advisors first reported a position in RGEN in Q3 2019 and held it in 10 quarters. The position peaked at $3M in Q4 2020. 442 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

Calamos Advisors reported no remaining Repligen position as of Q1 2026 after selling out during the quarter.
Calamos Advisors sold 3,362 Repligen shares in Q1 2026, an estimated $551K.
Calamos Advisors first reported a position in Repligen in Q3 2019 and held it in 10 quarters.
Calamos Advisors's Repligen position peaked at $3M in Q4 2020.
442 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.